Serum interleukin-27 levels in patients with cutaneous T-cell lymphoma: Viewpoints in dermatology • Correspondence

Clinical and Experimental Dermatology

Volumn 35, Issue 4, 2010, Pages

  Miyagaki, T ^a   Sugaya, M ^a   Shibata, S ^a   Ohmatsu, H ^a   Fujita, H ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 27; STEROID;

ADULT; ADVANCED CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; EOSINOPHIL COUNT; HUMAN; LETTER; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PRIORITY JOURNAL; SEZARY SYNDROME;

ADULT; AGED; HUMANS; INTERLEUKIN-17; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 77951222202     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03684.x     Document Type: Letter

References (5)

1. Pflanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity 2002 16 : 779 790. (Pubitemid 34786477)
2. Takeda A, Hamano S, Yamanaka A et al. Cutting edge. role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003 170 : 4886 4890. (Pubitemid 36554716)
3. Yoshimoto T, Yoshimoto T, Yasuda K et al. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007 179 : 4415 4423.
4. Hisada M, Kamiya S, Fujita K et al. Potent antitumor activity of interleukin-27. Cancer Res 2004 64 : 1152 1156. (Pubitemid 38176923)
5. Shimizu M, Shimamura M, Owaki T et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006 176 : 7317 7324. (Pubitemid 43849032)